TY - JOUR
T1 - Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis
AU - Jachs, Mathias
AU - Binter, Teresa
AU - Schmidbauer, Caroline
AU - Hartl, Lukas
AU - Strasser, Michael
AU - Laferl, Hermann
AU - Hametner-Schreil, Stephanie
AU - Lindorfer, Alexander
AU - Dax, Kristina
AU - Stauber, Rudolf E
AU - Kessler, Harald H
AU - Bernhofer, Sebastian
AU - Maieron, Andreas
AU - Loacker, Lorin
AU - Bota, Simona
AU - Santonja, Isabel
AU - Munda, Petra
AU - Mandorfer, Mattias
AU - Peck-Radosavljevic, Markus
AU - Holzmann, Heidemarie
AU - Gschwantler, Michael
AU - Zoller, Heinz
AU - Ferenci, Peter
AU - Reiberger, Thomas
N1 - Funding Information:
This study was supported by a research grant (DEPAU) from MYR GmbH to TR.
Funding Information:
Caroline Schmidbauer received travel support from Gilead, Abbvie and Gebro; and speaking honoraria from Abbvie. Stephanie Hametner‐Schreil received speaking honoraria and/or advisory board fees from: Gilead, Abbvie, Shionogi, Astellas, Intercept, Roche. Petra Munda received speaking honoraria from AbbVie, Gilead, MSD, Janssen, Roche, Intercept; travel support from AbbVie and Gilead; and consulting/advisory board fees from AbbVie, Gilead, MSD, Janssen, Roche and Intercept. M.M. served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol‐Myers Squibb, Gilead, Collective Acumen, and W. L. Gore & Associates and received travel support from AbbVie, Bristol‐Myers Squibb, and Gilead. M.P.‐R. received advisory and/or speaker honoraria from AstraZeneca, AbbVie, Amgen, Bayer, Behring, BMS, Eisai, Gilead, Intercept, Ipsen, Lilly, Merz, MSD, Roche, Sanofi, Shionogi, Sobi. M.G. received grants from AbbVie, Gilead, and MSD; speaking honoraria from AbbVie, Gilead, MSD, Janssen, Roche, Intercept; and consulting/advisory board fees from AbbVie, Gilead, MSD, Janssen, Roche and intercept. Peter Ferenci received an unrestricted research grant from Gilead, is on the safety review board of MyrPharma, consulting/advisory board fees from Viravaxx, speaking honoraria from AbbVie, Gilead. T.R. served as a speaker and/or consultant and/or advisory board member for AbbVie, Bayer, Boehringer Ingelheim, Gilead, Intercept, MSD, Siemens, and W. L. Gore & Associates and received grants/research support from AbbVie, Boehringer Ingelheim, Gilead, MSD, Philips, and W.L. Gore & Associates as well as travel support from Boehringer Ingelheim and Gilead. Mathias Jachs, Teresa Binter, Lukas Hartl, Michael Strasser, Hermann Laferl, Alexander Lindorfer, Kristina Dax, Rudolf E. Stauber, Harald H. Kessler, Sebastian Bernhofer, Andreas Maieron, Lorin Loacker, Simona Bota, Isabel Santonja, and Heidemarie Holzmann declare no conflicts of interest.
Publisher Copyright:
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
PY - 2021/12
Y1 - 2021/12
N2 - BACKGROUND: Hepatitis D virus (HDV) coinfection aggravates the course of hepatitis B virus (HBV). The prevalence of HDV in Austria is unknown.OBJECTIVE: This national study aimed at (i) recording the prevalence of HDV-infection in Austria and (ii) characterizing the "active" HDV cohort in Austria.METHODS: A total of 10 hepatitis treatment centers in Austria participated in this multicenter study and retrospectively collected their HDV patients between Q1/2010 and Q4/2020. Positive anti-HDV and/or HDV-RNA-polymerase chain reaction (PCR) results were retrieved from local database queries. Disease severity was assessed by individual chart review. Viremic HDV patients with clinical visits in/after Q1/2019 were considered as the "active" HDV cohort.RESULTS: A total of 347 anti-HDV positive patients were identified. In 202 (58.2%) patients, HDV-RNA-PCR test was performed, and 126/202 (62.4%) had confirmed viremia. Hepatocellular carcinoma was diagnosed in 7 (5.6%) patients, 7 (5.6%) patients underwent liver transplantation, and 11 (8.7%) patients died during follow-up. The "active" Austrian HDV cohort included 74 (58.7%) patients: Evidence for advanced chronic liver disease (ACLD, i.e., histological F3/F4 fibrosis, liver stiffness ≥10 kPa, varices, or hepatic venous pressure gradient ≥6 mmHg) was detected in 38 (51.4%) patients, including 2 (5.3%) with decompensation (ascites/hepatic encephalopathy). About 37 (50.0%) patients of the "active" HDV cohort had previously received interferon treatment. Treatment with the sodium-taurocholate cotransporting polypeptide inhibitor bulevirtide was initiated in 20 (27.0%) patients.CONCLUSION: The number of confirmed HDV viremic cases in Austria is low (<1% of HBV patients) but potentially underestimated. Testing all HBV patients will increase the diagnostic yield. More than half of viremic HDV patients had ACLD. Improved HDV testing and workup strategies will facilitate access to novel antiviral therapies.
AB - BACKGROUND: Hepatitis D virus (HDV) coinfection aggravates the course of hepatitis B virus (HBV). The prevalence of HDV in Austria is unknown.OBJECTIVE: This national study aimed at (i) recording the prevalence of HDV-infection in Austria and (ii) characterizing the "active" HDV cohort in Austria.METHODS: A total of 10 hepatitis treatment centers in Austria participated in this multicenter study and retrospectively collected their HDV patients between Q1/2010 and Q4/2020. Positive anti-HDV and/or HDV-RNA-polymerase chain reaction (PCR) results were retrieved from local database queries. Disease severity was assessed by individual chart review. Viremic HDV patients with clinical visits in/after Q1/2019 were considered as the "active" HDV cohort.RESULTS: A total of 347 anti-HDV positive patients were identified. In 202 (58.2%) patients, HDV-RNA-PCR test was performed, and 126/202 (62.4%) had confirmed viremia. Hepatocellular carcinoma was diagnosed in 7 (5.6%) patients, 7 (5.6%) patients underwent liver transplantation, and 11 (8.7%) patients died during follow-up. The "active" Austrian HDV cohort included 74 (58.7%) patients: Evidence for advanced chronic liver disease (ACLD, i.e., histological F3/F4 fibrosis, liver stiffness ≥10 kPa, varices, or hepatic venous pressure gradient ≥6 mmHg) was detected in 38 (51.4%) patients, including 2 (5.3%) with decompensation (ascites/hepatic encephalopathy). About 37 (50.0%) patients of the "active" HDV cohort had previously received interferon treatment. Treatment with the sodium-taurocholate cotransporting polypeptide inhibitor bulevirtide was initiated in 20 (27.0%) patients.CONCLUSION: The number of confirmed HDV viremic cases in Austria is low (<1% of HBV patients) but potentially underestimated. Testing all HBV patients will increase the diagnostic yield. More than half of viremic HDV patients had ACLD. Improved HDV testing and workup strategies will facilitate access to novel antiviral therapies.
KW - Adult
KW - Austria/epidemiology
KW - Carcinoma, Hepatocellular/epidemiology
KW - Disease Progression
KW - Female
KW - Hepatitis D/diagnosis
KW - Humans
KW - Liver Cirrhosis/epidemiology
KW - Liver Neoplasms/epidemiology
KW - Male
KW - Middle Aged
KW - Prevalence
KW - Retrospective Studies
UR - http://www.scopus.com/inward/record.url?scp=85119676469&partnerID=8YFLogxK
U2 - 10.1002/ueg2.12163
DO - 10.1002/ueg2.12163
M3 - Journal article
C2 - 34873866
SN - 2050-6406
VL - 9
SP - 1119
EP - 1127
JO - United European Gastroenterology Journal
JF - United European Gastroenterology Journal
IS - 10
ER -